目的：探讨宫颈上皮内瘤变（cervical intraepithelial neoplasia， CIN）患者治疗前人乳头瘤病毒L1（human papillomavirus late 1， HPV-L1）壳蛋白的表达能否成为预测治疗后疾病转归的指标。方法：通过免疫组化法检测CIN患者治疗前HPV-L1壳蛋白表达；通过导流杂交基因芯片技术检测CIN患者高危型人乳头瘤病毒（high-risk human papillomavirus， HR-HPV）DNA的表达。结果：（1）CIN患者3种治疗方法比较，HR-HPV持续感染率差异无统计学意义（P＞0．05）。（2）治疗前CINⅠ的涂片中HPV-L1壳蛋白阳性表达率为75．00％，CINⅡ～Ⅲ的涂片中HPV-L1壳蛋白阳性表达率为36．13％，两者比较差异有显著统计学意义（P＜0．05）。（3）治疗前HPV-L1壳蛋白阳性的CIN患者，术后12个月随访中HR-HPV持续感染率为5．97％；而治疗前HPV-L1壳蛋白阴性的CIN患者，术后12个月随访中HR-HPV持续感染率为19．05％。两组比较差异有显著统计学意义（P＜0．05）。（4）CIN患者治疗前HPV-L1壳蛋白表达与治疗后12个月HR-HPV持续感染呈负相关。结论：CIN患者治疗前HPV-L1壳蛋白的检测有可能成为评估CIN患者治疗后预测疾病转归的指标。%Objective To investigate the possibility of human papillomavirus late 1 (HPV-L1) protein detection in predicting the prognosis of cervical intraepithelial neoplasia (CIN). Methods (1)Through immunocytochemical method to detect expression of HPV-L1 protein in diagnosis of CIN before treatment. (2) Through hybridization and gene chip technology to detect expression of high-risk human papilloma virus (HR-HPV) in diagnosis of CIN after treatment for twelve months. Results (1) Comparing the three treatment methods in CIN patients, HR-HPV infection sustained no significant difference (P > 0.05). (2) The positive expression rate of HPV-L1 protein was 75.00% in CINⅠand 36.13%in CINⅡ~Ⅲbefore treatment, with statistically significant (P<0.05). (3) Persistent infection rate of HR-HPV was 5.97%in HPV-L1 positive expression group after treatment for twelve months and 19%in HPV-L1 negative expression group. The difference between the two was statistically significant (P<0.05). (4) The expression of HPV-L1 capsid protein before treatment had a negative relationship with HR-HPV persistent infection after 12 months of treatment. Conclusion Detection of HPV-L1 protein before treatment can predict the prognosis of CIN which had been treated.
展开▼
